Compare Corsair Gaming Inc (CRSR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Merck & Co., Inc. — how do they compare? Corsair Gaming Inc trades at $9.55 (market cap $1.03B), while Merck & Co., Inc. trades at $123.42 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 289.6× Corsair Gaming Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals.
| CRSR | MRK | |
|---|---|---|
Market Cap | $1.03B | $298.31B |
Sector | Technology | Health |
52-Week High | $12.14 | $129.52 |
52-Week Low | $4.58 | $77.60 |
Enterprise Value | $1.10B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSR trades at $9.47, down 1.97% today, with a bullish technical signal from moving averages and a consensus analyst price target of $9.00. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q3 2025 missed. Revenue for 2025 was $1.47B with a net loss of $16.16M, but 2026 projects a net profit of $7M. Positive news includes AI product launches and partnerships, driving investor optimism amid a mixed analyst rating of 4 Buy and 7 Hold.
Outlook is cautiously optimistic with potential from AI expansion and earnings growth, but risks include thin profit margins and competitive pressures. The stock's current price near the consensus target suggests limited upside, requiring strong execution for further gains. Investors should weigh the bullish technicals against fundamental challenges in the gaming hardware sector.
Merck (MRK) trades at $123.6, down 0.35% today, with a bullish technical signal and strong institutional interest. Recent earnings have consistently beaten estimates, including Q1 2026, and the company is acquiring Terns Pharmaceuticals to bolster its oncology pipeline. The stock shows robust profitability with a net income margin of 28.07% in 2025 and a consensus analyst price target of $137.30, indicating potential upside.
The outlook remains positive due to earnings momentum and strategic acquisitions, though risks include rising debt levels and competitive pressures. Investors should weigh the strong analyst buy consensus against execution risks in integrating new assets and macroeconomic uncertainties affecting the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
